Bedford, MA (September 2015) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today closure of $3.5 Million in series A financing. The financing will be used to continue developing tests to rapidly detect hospital infections and determine their susceptibility to antibiotics.
About First Light Biosciences
Based in Bedford, Massachusetts, First Light Biosciences is developing breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for the infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with affordability and ease-of-use. To learn more, visit www.firstlightibio.com